

DAFTAR PUSTAKA

- Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., *et al.* 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 29: 1303-1310.
- Angus D.C., van der Poll T., 2013. Severe Sepsis and Septic Shock, *NEJM* 369; 840-851
- Ansar W., Ghosh S., 2013. C-reactive protein and the biology of disease. *Immunol Res* 56:131–142
- Assicot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., 1993. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet* 1993; 341: 515-518.
- Balc I.C., Sungurtekin H., Gürses E., Sungurtekin U., Kaptanoglu B., 2003. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. *Crit Care* 7: 85-90.
- Brodská H., Malicková K., Adamková V., Benáková H., Státná M.M., Zima T., 2013. Significantly higher procalcitonin levels could differentiate Gram negative sepsis from gram positive and fungal sepsis, *Clin Exp Med* (2013) 13:165-170
- Becker K.L., Nylén E.S., White J.C., Müller B., Snider R.H., 2004. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab* 89: 1512-1525
- Becker K.L., Snider R., Nylén E.S., 2010. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *Br J Pharmacol* 159: 253-264.
- Bouadma L., Luyt C.E., Tubach F., *et al.* 2010. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010; 375:463–474
- Charles P.E., Ladoire S., Aho S., Quenot J.P., Doise J.P., Prin S., *et al.* 2008. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. *BMC Infect Dis* 8:38-46

- Charles, P.E. *et al.* 2009. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. *Crit.Care* 13:16-20.
- Cho S.Y., Choi J.H., 2014. Biomarkers of Sepsis. *Infect Chemother* 2014; 46(1):1-12
- Christ-Crain M., Jaccard-Stolz D., Bingisser R., 2004. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single blinded intervention trial. *Lancet* 2004; 363:600–607
- Clayton J., 2013. Procalcitonin (serum, plasma). *Association for Clinical Biochemistry* 2013
- Dahlan M.S., 2013. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. *Salemba Medika*.
- Faix J.D., 2013. Biomarkers of sepsis. *Crit Rev Clin Lab Sci* 50: 23-36.
- Gilbert D.N., 2011. Procalcitonin as a biomarker in respiratory tract infection. *Clin Infect Dis* 52 Suppl 4: S346-350.
- Gilbert D.N., 2012. Serum procalcitonin levels. It is all about confidence. *Arch Intern Med* 2012;172:722-23.
- Hochreiter M., Kohler T., Schweiger A.M., *et al.* 2009. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomised prospective controlled trial. *Crit Care* 2009; 13: R83.
- Jeong S, Park Y., Cho Y., *et al.*, 2012. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. *Clin Chim Acta* 413:1731–1736
- Karzai W., Oberhoffer M., Meier-Hellmann A., Reinhart K., 1997. Procalcitonin-a new indicator of the systemic response to severe infections. *Infection* 25:329-334.
- Kemenkes, 2017. Pedoman Nasional Pelayanan Kedokteran Tata laksana Sepsis, Diunduh dari: www.hukor.kemkes.go.id pada tanggal 5 Desember 2020
- Koivula I., Hamalainen S., Jantunen E., *et al.* 2011. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. *Scand J Infect Dis* 2011;43:471–478

- Kristoffersen K.B., Sogaard O.S., Wejse C., Black F.T., Greve T., Tarp B., *et.al.*, Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission-a randomized trial. *Clin Microbiol Infect* 2009; 15:481-7
- Lakna P., 2107. Difference between Gram positive and Gram Negative Bacteria. Diunduh dari: www.researchgate.net/publication/315757324 on 17th July 2018
- Lee H., 2013. Procalcitonin as a biomarker of infectious diseases. *Korean J Intern Med* 2103; 28:285-291
- Lever A., Mackenzie I., 2007. Sepsis: definition, epidemiology, and diagnosis. *BMJ* 335: 879-883.
- Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D.C., *et al.* 2003. 2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 31: 1250-1256.
- Li S., *et al.* 2016 Serum procalcitonin levels distinguish Gram-negative bacterial sepsis from Gram-positive bacterial and fungal sepsis. *Journal of Research Medical Science, Walters Kluwer-Medknow*
- Lin Jiang-Chang, Chen Zhao-Hong and Chen Xiao-Dong. 2020. Elevated serum procalcitonin predicts gram negative bloodstream infection in patient with burns. *J BURNS*. 46: 182-9.
- Liu H.H., Zhang M.W., Guo J B, Li J, Su L., 2016. Procalcitonin and C-reactive protein in early diagnosis of sepsis caused by either Gram-negative or Gram-positive bacteria. *Ir J Med Sci* 2016; DOI 10.1007/s11845-016-1457-z
- Loehoeri S, Subroto YW., 2003, Profil pasien yang didiagnosis dengan Sepsis di bangsal Penyakit Dalam RS Sardjito tahun 2003, *Dalam Berkala Ilmu Kedokteran* 2003, XXXV (4)
- Lu X.L, Xiao Z.H., Yang M.Y., Zhu Y.M., 2013. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. *Nephrol Dial Transplant* 28: 122-129.
- Marnell L., Mold C., Du Clos T.W., 2005. C-reactive protein: ligands, receptors and role in inflammation. *Clin Immunol* 2005; 117 : 104-11

- Martin G.S., Brunkhorst F.M., Janes J.M., *et al.* 2009 The international progress registry of patients with severe sepsis: drotrecogin (activated) use and patient outcomes. *Crit Care* 13:R103
- Martin G.S., 2012. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. *Expert Rev Anti Infect Ther* 10: 701-706.
- Maruna P., Nedelínková K., Gürlich R., 2000. Physiology and genetics of procalcitonin. *Physiol Res* 49 Suppl 1: S57-61.
- Meisner M., 2002. Pathobiochemistry and clinical use of procalcitonin. *Clin Chim Acta* 323: 17-29
- Meisner M., 2014 Update on procalcitonin measurements. *Ann Lab Med* 34:263-273.
- Meisner M., 2005. Biomarkers of sepsis: clinically useful? 2. *Curr Opin Crit Care* 2005; 11 : 473-80.
- Mitaka C., 2005. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. *Clin Chim Acta* 2005; 351 : 17-29.
- Müller B., Becker K.L., 2001. Procalcitonin: how a hormone became a marker and mediator of sepsis. *Swiss Med Wkly* 2001; 131: 595-602.
- Müller B., Becker K.L., Schächinger H., Rickenbacher P.R., Huber P.R., *et al.*, 2000. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. *Crit Care Med* 28: 977-983.
- Munford R.S., 2008. Severe Sepsis and Septic Shock in Harrison's Principles of Internal Medicine, 17th Edition, Mc Graw Hill Medical
- Munford R.S., Suffredini A.F., 2014. Sepsis, Severe Sepsis and Septic Shock. In: Bennett John E, Dolin Raphael, Blaser Martin J, Mandell Douglas, and Bennett's Principles and Practice of Infectious Diseases. (8th edn), Philadelphia, Elsevier Health Sciences, 914-934.
- Nainggolan, J.J.P., Kumaat, L.T., Laihad, M.L. 2017. Gambaran suber terjadinya infeksi pada penderita sepsis dan syok septik di ICU RSUP Prof. Dr. R. Kandou Manado Periode Agustus 2006 sampai dengan September 2017. *J e-Clinical (eCI)*. Vol.5:2.
- Notoatmodjo, S., 2010. *Metodologi penelitian kesehatan*. Rieka Cipta, Jakarta.

- Paudel R., Dogra P., Yates A.A.M., Yataco, A.C., 2020. Procalcitonin: A Promising tool or just another overhyped test? *Int. J. Med Sci.* 2020 Vol. 17
- Prucha M., Bellingan G., Zazula R., 2015. Sepsis biomarkers. *ClinChim Acta* 440:97–103
- Ranniko, J., *et al.*, 2017. Sepsis-related mortality in 497 cases with blood culture-positive sepsis in an emergency department. *International Journal of Infectious Diseases* 58 (2017) 52–57
- Reimer L.G., Wilson M.L., Weinstein M.P., 1997. Update on detection of bacteremia and fungemia. *Clin Microbiol Rev* 1997; 10 : 444-65.
- Rimac V., 2015. Procalcitonin: potential, limitations and availability. *Signa Vitae* 2015;10(suppl1):84-86
- Shiferaw B., Bekele E., Kumar K., Boutin A, Frieri M., 2016. The Role of Procalcitonin as a Biomarker in Sepsis. *Journal of Infectious disease and Epidemiology* 2016, 2:006
- Singer M., Deutschman C.S., Seymour C.W., *et al.*, 2016 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); *JAMA* 2016;315(8):801-810
- Soreng C., Levy R M.S., 2011. Procalcitonin: an Emerging Biomarker of Bacterial Sepsis. *Microbiology Newspaper* 33:171-178
- Stearns-Kurosawa D.J., Osuchowski M.F., Valentine C., Kurosawa S., RemicD.G., 2011. The pathogenesis of sepsis. *Annu Rev Pathol* 6: 19-48.
- Tamaki K., Kogata Y., Sugiyama D., Nakazawa T., Hatachi S., *et al.* 2008 Diagnostic Accuracy of Serum Procalcitonin Concentrations for Detecting Systemic Bacterial Infection in Patients with Systemic Autoimmune Diseases. *J Rheumatol* 35:114-119
- Tavares E., Miñano F.J., 2010. Immunoneutralization of the amino procalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia neuroendocrine and systemic studies. *Clin Sci (Lond)* 119: 519-534
- Uzzan B., Cohen R., Nicolas P., *et al.* 2006. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. *Crit Care Med* 2006; 34:1996–2003

- Vijayan, A.L., Vanimaya, Ravindran S., Saikant R., Lakshmi S., Kartik R., *et al.*, 2017. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *Journal of Intensive Care* (21017)5:51
- Wang H.E., Shapiro N.I., Griffin R., Safford M.M., Judd S., Howard G. 2102. Chronic medical conditions and risk of sepsis. *PLoS One* 2012;7:e48307
- Wiedermann F.J., Kaneider N., Egger P., Tiefenthaler W., Wiedermann C.J., Lindner K.H., *et al.* 2002. Migration of human monocytes in response to procalcitonin. *Crit Care Med* 2002;30:1112-7